Mr. Speaker, I am speaking tonight about the opioid crisis and the organizations responsible for causing the opioid crisis.
It is now a matter of public record that Purdue Pharma, a pharmaceutical company, developed oxycontin, mislabelled it, misbranded it and actively promoted it in such a way that fuelled and, I think, in many respects, caused the opioid crisis that has killed so many people and devastated so many families here in Canada and around the world. In response to these actions by Purdue Pharma there have been various lawsuits, especially in the United States, that have sought to hold Purdue accountable.
Notably, in the timeline of Purdue's actions and subsequent measures to hold it accountable, Purdue was found guilty of criminal misbranding their product in a way that downplayed risks and contributed to the opioid crisis. It was found guilty in 2007.
The company, McKinsey & Company, that we have been speaking about in this House, did work for Purdue Pharma for a period of about 15 years and that spanned from 2004 until about 2019. In other words, most of the work done by McKinsey & Company for Purdue Pharma happened after Purdue had already been found guilty of criminal misbranding.
When McKinsey was brought on, part of its mandate was to figure out how to address, in the face of escalating criticism over Purdue's actions, concerns about the tapering off of opioid sales. McKinsey approached this is in a totally amoral way, coming back with recommendations that showed no regard for those suffering from addiction, no regard for the impact on communities and families, but instead looked exclusively at how to increase, or in their words, turbocharge, the sale of opioids.
Some of the recommendations that McKinsey brought to Purdue Pharma on how to do that are truly horrifying in their disregard for human life and well-being. McKinsey had proposed, for example, that bonuses could be paid out to pharmacists in instances where there were overdoses. McKinsey also proposed that, in order to get around checks that were being put in place in traditional pharmacies to try to control over-prescription and address addiction issues, Purdue could try to circumvent those controls by having a mail-in system whereby people could access opioids through the mail. Those were the kinds of proposals that McKinsey was bringing to Purdue Pharma.
For about two-thirds of that 15-year period that McKinsey was working for Purdue Pharma, Dominic Barton was the managing director. He claimed at committee to have absolutely no knowledge of what was going on during this time. The fact of the matter is that he was the managing director of this company that for 15 years was doing work for Purdue Pharma, advising them on how to turbocharge opioid sales, showing no concern, no regard whatsoever for the impact that this was having on human life and on families and communities throughout North America and around the world.
As a result of the advice provided by McKinsey, McKinsey had to pay a settlement in the hundreds of millions of dollars in the United States. Meanwhile, the government has a clear, close relationship with McKinsey and Dominic Barton.
I asked the government this question that I would like to ask again tonight. Did the Prime Minister or members of his cabinet ever discuss opioid policy with Dominic Barton or the senior leadership of McKinsey?